ALNY — Alnylam Pharmaceuticals Inc. price, chart and key statistics

Price data

Price

$246.74

Change YTD

-37.95%

Next earnings

Oct 29, 2026

Market cap

33B2016-12 3.2B2026-09 33B+927.6% over the window

Enterprise value

31.6B

Shares outstanding

133.8M2016-06 85.7M2026-06 133.8M+56.1% over the window

52W low

$197.81

52W high

$495.55

From 52W high

-50.21%

From 52W low

+24.74%

52W range

16%

Beta

0.29

Volume

Rel volume

0.67×

30D volume

1.5M

30D $ vol

380.8M

Fundamentals

Sales (ttm)

4.8B2016-12 47.2M2026-06 4.8B+10087.2% over the window

Sales/share

$35.902016-12 $0.552026-06 $35.90+6448.4% over the window

EPS (ttm)

$5.332019-12 -$8.112026-06 $5.33-165.7% over the window

FCF (ttm)

819.9M2016-06 -295.2M2026-06 819.9M-377.7% over the window

FCF/share

$6.132016-06 -$3.442026-06 $6.13-277.9% over the window

Book value/share

$10.122016-06 $12.812026-06 $10.12-21.0% over the window

Net margin

15.26%2016-12 -869.6%2026-06 15.3%-101.8% over the window

ROE

54.14%2016-06 -32.8%2026-06 54.1%-264.9% over the window

ROA

13.19%2016-06 -26.1%2026-06 13.2%-150.5% over the window

Current ratio

3.052016-06 12.582026-06 3.05-75.7% over the window

Growth (CAGR, ttm) · 10Y

Sales

+95.23%2025-06-30 → 2026-06-302.5B → 4.8B (+95.1% total)+57.15%2023-06-30 → 2026-06-301.2B → 4.8B (+288.3% total)+47.53%2021-06-30 → 2026-06-30687.5M → 4.8B (+598.8% total)+62.74%2016-12-31 → 2026-06-3047.2M → 4.8B (+10087.2% total)

Shares

+2.08%2025-06-30 → 2026-06-30131.1M → 133.8M (+2.1% total)+2.30%2023-06-30 → 2026-06-30125M → 133.8M (+7.0% total)+2.40%2021-06-30 → 2026-06-30118.8M → 133.8M (+12.6% total)+4.55%2016-06-30 → 2026-06-3085.7M → 133.8M (+56.1% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share

+91.24%2025-06-30 → 2026-06-30$18.78 → $35.90 (+91.2% total)+53.63%2023-06-30 → 2026-06-30$9.90 → $35.90 (+262.7% total)+44.07%2021-06-30 → 2026-06-30$5.79 → $35.90 (+520.6% total)+55.34%2016-12-31 → 2026-06-30$0.55 → $35.90 (+6448.4% total)

Book value/share

+139.00%2025-06-30 → 2026-06-30$4.24 → $10.12 (+138.9% total)n/a+7.10%2021-06-30 → 2026-06-30$7.18 → $10.12 (+40.9% total)-2.33%2016-06-30 → 2026-06-30$12.81 → $10.12 (-21.0% total)

Price

-45.91%2025-09-30 → 2026-09-30$456.00 → $246.74 (-45.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+11.67%2023-09-29 → 2026-09-30$177.10 → $246.74 (+39.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+5.50%2021-09-30 → 2026-09-30$188.81 → $246.74 (+30.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+13.43%2016-09-29 → 2026-09-30$69.94 → $246.74 (+252.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.

Total return

-45.91%2025-09-30 → 2026-09-30$456.00 → $246.74 (-45.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+11.67%2023-09-29 → 2026-09-30$177.10 → $246.74 (+39.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+5.50%2021-09-30 → 2026-09-30$188.81 → $246.74 (+30.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+13.43%2016-09-29 → 2026-09-30$69.94 → $246.74 (+252.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.

46.3×2016-12 -8.282026-09 45.03-643.7% over the window

Fwd P/E

20.5×

P/S (ttm)Market cap ÷ TTM revenue.

6.9×2016-12 33.342026-09 6.87-79.4% over the window

P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.

24.4×2016-12 3.172026-09 24.38+670.2% over the window

P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).

40.3×2016-12 -9.732026-09 40.27-513.9% over the window

EV/EBITDA (fy)

29.9×

EV/Sales (ttm)

6.6×

FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.

2.48%2016-09 -10.3%2026-06 2.0%-119.8% over the window

Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 133.8M ÷ 131.1M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.

-2.08%

Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-2.08%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($42.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.

-2.08%

Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($33B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.

0.00%2016-09 0.0%2026-06 0.0%

Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($33B). Same caveat as the cash buyback yield.

0.00%2016-09 0.0%2026-06 0.0%

Vs own 10Y history

P/S

1st

P/B

61st